Overview
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Description
The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.
Eligibility
Inclusion Criteria:
- Stage I-III at initial NSCLC diagnosis
- Aged ≥18 years at first diagnosis of NSCLC
- Timeframe of NSCLC diagnosis:
For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027
Exclusion Criteria:
- NSCLC is not the primary cancer diagnosis
- Patients with a recent history of other tumor or concurrent other tumor
- Patients participating in interventional clinical trials at time of initial diagnosis
- Patients with positive pregnancy status at the time of diagnosis
